Supplementary e-Appendix 1

Exclusion criteria in studies 1 (RES113817) and 2 (RES117178). For both studies, use of short-acting bronchodilators and long-acting bronchodilators within 6 hours or 12 hours, respectively, of study visits was not permitted. Participants were required to have no history of acute respiratory disease or exacerbation within 4 weeks of the study (2 weeks for Study 2, as long as their usual stable baseline lung function had returned), and no history of any other inflammatory lung condition or carcinoma of the lung (except in Study 2, where patients with previous lung cancer that had been fully treated and who had been free of the disease for at least 5 years could be included). Females were only eligible if they were not of child-bearing potential or had a negative pregnancy test at Screening and during the study visit, because HRCT scanning was performed for the assessment of exploratory endpoints (ACR–SPR Practice Guideline 2013. Available at http://www.acr.org/~/media/9E2ED55531FC4B4FA53EF3B6D3B25DF8.pdf. Accessed February 19, 2015).